-transparent.png){kind=logo}
The serum ferritin level was raised in 34 of 35 (97%) patients with hepatocellular carcinoma and in 20 of 23 (87%) with uncomplicated cirrhosis. Levels rose following therapeutic embolisation in 14 of 15 patients and continued to rise in 85% of all tumor patients who showed no clinical response to chemotherapy (intravenous Adriamycin) whereas in those who did respond the serum ferritin level fell. By contrast, there was a fall in serum alphafetoprotein immediately after embolisation but like serum ferritin, alphafetoprotein levels rose with disease progression and only fell in those achieving clinical remission. Serum ferritin has no role in the differential diagnosis of hepatocellular carcinoma but may be a useful marker in monitoring response to chemotherapy particularly in the alphafetoprotein-negative patient.
W M Melia, and
S Bullock, and
P J Johnson, and
R Williams
August 1977,
Cancer,
W M Melia, and
S Bullock, and
P J Johnson, and
R Williams
February 1988,
Hepato-gastroenterology,
W M Melia, and
S Bullock, and
P J Johnson, and
R Williams
January 1991,
Gastroenterologie clinique et biologique,
W M Melia, and
S Bullock, and
P J Johnson, and
R Williams
January 1977,
Oncology,
W M Melia, and
S Bullock, and
P J Johnson, and
R Williams
December 1985,
Hepato-gastroenterology,
W M Melia, and
S Bullock, and
P J Johnson, and
R Williams
January 1984,
Digestion,
W M Melia, and
S Bullock, and
P J Johnson, and
R Williams
August 1984,
The American journal of gastroenterology,
W M Melia, and
S Bullock, and
P J Johnson, and
R Williams
January 1995,
Tropical and geographical medicine,
W M Melia, and
S Bullock, and
P J Johnson, and
R Williams
May 1984,
Cancer,
W M Melia, and
S Bullock, and
P J Johnson, and
R Williams
November 2014,
Journal of gastroenterology and hepatology,
